How I treat MDS after hypomethylating agent failure
V Santini - Blood, The Journal of the American Society of …, 2019 - ashpublications.org
Hypomethylating agents (HMA) azacitidine and decitabine are standard of care for
myelodysplastic syndrome (MDS). Response to these agents occurs in∼ 50% of treated …
myelodysplastic syndrome (MDS). Response to these agents occurs in∼ 50% of treated …
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
B Ball, A Zeidan, SD Gore, T Prebet - Leukemia & lymphoma, 2017 - Taylor & Francis
The hypomethylating agents (HMA) azacitidine and decitabine are both approved by the
FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a …
FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a …
Failure of hypomethylating agent–based therapy in myelodysplastic syndromes
TM Kadia, E Jabbour, H Kantarjian - Seminars in oncology, 2011 - Elsevier
Hypomethylating agents such as 5-azacytidine or decitabine have been a major
breakthrough in the treatment of patients with myelodysplastic syndromes (MDS). They have …
breakthrough in the treatment of patients with myelodysplastic syndromes (MDS). They have …
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial …
M Cabrero, E Jabbour, F Ravandi, Z Bohannan… - Leukemia research, 2015 - Elsevier
Hypomethylating agents (HMA), such as 5-azacitidine or decitabine, are currently used to
treat patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) until …
treat patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) until …
Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical …
EJ Jabbour, G Garcia‐Manero, P Strati, A Mishra… - Cancer, 2015 - Wiley Online Library
BACKGROUND The hypomethylating agents (HMAs) azacitidine and decitabine are most
commonly used to treat patients with higher‐risk myelodysplastic syndromes (MDS). To the …
commonly used to treat patients with higher‐risk myelodysplastic syndromes (MDS). To the …
Hypomethylating agents and other novel strategies in myelodysplastic syndromes
G Garcia-Manero, P Fenaux - Journal of Clinical Oncology, 2011 - ascopubs.org
Over the last decade, treatment approaches for patients with myelodysplastic syndromes
(MDS) have improved significantly. Treatment of MDS is tailored to the specific risk …
(MDS) have improved significantly. Treatment of MDS is tailored to the specific risk …
[HTML][HTML] Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes
CR Cogle, I Imanirad, LE Wiggins… - Clin Adv …, 2010 - hematologyandoncology.net
Recently, several new therapies have become available to treat patients with
myelodysplastic syndromes (MDS). Azanucleosides such as azacitidine (Vidaza, Celgene) …
myelodysplastic syndromes (MDS). Azanucleosides such as azacitidine (Vidaza, Celgene) …
Novel therapeutic strategies: hypomethylating agents and beyond
V Santini - Hematology 2010, the American Society of …, 2012 - ashpublications.org
The treatment of symptomatic and high-risk myelodysplastic syndrome (MDS) spans several
therapeutic goals and options. Key to the successful therapy of these heterogeneous …
therapeutic goals and options. Key to the successful therapy of these heterogeneous …
Low-dose decitabine versus low-dose azacitidine in lower-risk MDS
K Sasaki, E Jabbour, G Montalban-Bravo… - NEJM …, 2022 - evidence.nejm.org
Background The hypomethylating agents are part of the standard of care in the treatment of
myelodysplastic syndromes (MDS), but their role in patients with lower-risk disease is …
myelodysplastic syndromes (MDS), but their role in patients with lower-risk disease is …
Epigenetic therapies in MDS and AML
EA Griffiths, SD Gore - Epigenetic Alterations in Oncogenesis, 2012 - Springer
The use of low dose hypomethylating agents for patients with myelodysplastic syndrome
(MDS) and secondary acute myeloid leukemia (AML) has had made a significant impact. In …
(MDS) and secondary acute myeloid leukemia (AML) has had made a significant impact. In …